1Mancia G,de Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:the Fask Force for the Management of Arteria Hypertension of the European society of Hypertension(Esc)[J].Eur heart J,2007,28(12):1462-1536.
2Moster M,staro JF.Resistant or difficult-to-control hypertension hypertension[J].N Engl J Med,2006,355(4):385-392.
3Ubaid-Girioli S,Ferreira-Melo SE,Souza LA,et al.Aldosterone escape with diuretic or angiotension-converting enzyme inhibitor/angitensioⅡreceptor blocker combination therapy in patients with mild to moderate hypertension[J].J Clin hypertens (Greenwich),2007,9(10):770-774.
4Miyazaki M,Takai S.Tissue angiotensionⅡgenerating system by angiotension-converting enzyme and chymase[J].J Pharmacol Sci,2006,100(5):391-397.
5Ouzan J,Perault C,Lincoff AM,et al. The role of spironolactone in the treatment of patients with refractor hypertension[J].Am J Hypertens,2002,15(4)925-930.
6Nishizaka MK,zaman MA,Calhoun DA.Efficacy of low-dose spironolacton in subjects with resistant hypertension[J].Am J Hypertens,2003,16(11pt1):925-930.
7Mahmud A,Mahgoub M,Hall M,et al.Dose aldosterone-to-renin radio predict the antihypertensive effect of the aldosterone antagonist spironolactone[J].Am J Hypertens,2005, 18(12pt1):1631-1635.
